Previous 10 | Next 10 |
2023-07-07 12:50:55 ET Gainers: Prestige Wealth ( PWM ) +90% . Castle Biosciences ( CSTL ) +52% . Near Intelligence ( NIR ) +44% . T2 Biosystems ( TTOO ) +37% . Greenidge Generation Holdings ( GREE ) +31% . The Real Good Food...
2023-07-07 10:07:00 ET Gainers: Castle Biosciences ( CSTL ) +43% . CareDx ( CDNA ) +20% . COMPASS Pathways ( CMPS ) +9% . TG Therapeutics ( TGTX ) +9% . KalVista Pharmaceuticals ( KALV ) +8% . Losers: PainReform ( P...
2023-07-06 13:08:25 ET Gainers: EdtechX Holdings Acquisition ( EDTX ) +40% . Mullen Automotive ( MULN ) +35% . Genius Sports Limited ( GENI ) +21% . Incannex Healthcare Limited ( IXHL ) +19% . Sweetgreen ( SG ) +18% . urban-g...
2023-07-06 11:25:40 ET Top-line phase 2b results indicated that ASLAN Pharmaceuticals ( NASDAQ: ASLN ) eblasakimab was effective in treating atopic dermatitis when dosed monthly. Data showed that 600mg of eblasakimab dosed once every four weeks led to 62.7% of patien...
2023-07-06 08:32:06 ET Allarity Therapeutics ALLR -53% after pricing public offering to $11M ASLAN Pharmaceuticals Limited ( ASLN ) -33% to host webcast on July 6, 2023, to discuss phase 2b topline data from TREK-AD trial evaluating Eblasakimab in atopic dermatitis. ...
Eblasakimab is the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation comparable to once every two weeks, supporting advancement to Phase 3. 600mg eblasakimab dosed once every ...
SAN MATEO, Calif. and SINGAPORE, July 05, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, will host a webcast to discuss the to...
SAN MATEO, Calif. and SINGAPORE, June 23, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the publication of da...
2023-06-22 11:21:31 ET ASLAN Pharmaceuticals ( NASDAQ: ASLN ) has licensed its atopic dermatitis candidate eblasakimab to Zenyaku Kogyo for Japanese rights. Terms call for ASLAN ( ASLN ) to receive $12M upfront, $3M in milestone payments from TREK-AD Phase 2b trial da...
ASLAN will receive up to $15 million in upfront and near-term payments and up to an additional $123.5 million based on development and commercial milestones plus tiered royalties on sales in percentages ranging up to low twenties Zenyaku Kogyo, a leading Japanese pharmaceutical company sp...
News, Short Squeeze, Breakout and More Instantly...
ASLAN Pharmaceuticals Limited Company Name:
ASLN Stock Symbol:
NASDAQ Market:
Translational data presented during a late-breaker poster session from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD indicates that eblasakimab performed better than dupilumab in improving airway function and ...
Positive interim data readout from 22 patients in TREK-DX study of eblasakimab showed unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab -experienced AD patients treated with 400mg eblasakimab weekly ...